Generic Name and Formulations:
Ciprofloxacin 6% (60mg/mL); otic susp; preservative-free.
Indications for OTIPRIO:
Bilateral otitis media with effusion undergoing tympanostomy tube placement. Acute otitis externa due to P. aeruginosa and S. aureus.
Adults and Children:
<6mos: not established. For intratympanic or otic administration only. ≥6mos: Otitis media: give as one 0.1mL (6mg) single dose into each affected ear, following suctioning of middle ear effusion. Otitis externa: give as one 0.2mL (12mg) single dose to the external ear canal of each affected ear.
Potential for microbial overgrowth (eg, bacteria, fungi); if infections occur, use alternatives. Pregnancy.
Nasopharyngitis, irritability, ear pruritus, headache, otitis media, ear discomfort.
Single-patient use vial—1mL
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally